Literature DB >> 7249794

Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life.

K Stoeckel.   

Abstract

The total (bound and unbound) plasma concentration time profiles following the three intravenous doses of Rocephin (150, 500 and 1,500 mg) declined in a biphasic manner. A simple compartment analysis was inappropriate since a dose-disproportional increase in the area under the total drug concentration time curve (AUCT,0(-8)) occurred. This resulted in unstable, dose-dependent total systemic clearance (9.7-13.0 ml/min) and volume of distribution (7.0-8.6 litres) values. The dose-dependent pharmacokinetic changes could be completely explained in terms of the concentration-dependent plasma protein binding (fp ranging from 0.04 to 0.17 in the concentration range from 0.5 to 300 micrograms/ml). Hence, the pharmacokinetics of free (unbound) Rocephin was linear and dose-independent. With reference to free (unbound) drug the mean total clearance was 255 ml/min and the mean renal clearance about 160 ml/min. The renal clearance was therewith slightly higher than the average glomerular filtration rate in man (approximately 125 ml/min). Consequently the coadministration of probenecid (1 g) had no effect on the pharmacokinetics of Rocephin. The mean plasma half-life of Rocephin was not influenced by dose and averaged 8 h. It was therewith the longest ever reported one for a cephalosporin in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249794     DOI: 10.1159/000238028

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  34 in total

1.  Disposition kinetics, bioavailability and renal clearance of cefepime in calves.

Authors:  M M Ismail
Journal:  Vet Res Commun       Date:  2005-01       Impact factor: 2.459

2.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

3.  Comparison of the serum bactericidal activity of ceftriaxone/piperacillin and ceftriaxone/netilmicin.

Authors:  K Machka; M Röbl; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

4.  Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs.

Authors:  A Cavalier; D Levêque; J D Peter; J Salmon; H Elkhaïli; Y Salmon; P Nobelis; J Geisert; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 5.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 6.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

7.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

Review 8.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 10.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.